Piper Sandler Downgrades Kinnate Biopharma to Neutral, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has downgraded Kinnate Biopharma from Overweight to Neutral and lowered the price target from $20 to $4.
September 19, 2023 | 8:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kinnate Biopharma has been downgraded from Overweight to Neutral by Piper Sandler, with a lowered price target from $20 to $4.
The downgrade from Overweight to Neutral by Piper Sandler, along with a significant reduction in the price target, indicates a less optimistic outlook for Kinnate Biopharma. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100